Mirae Asset Global Investments
RVNC

Mirae Asset Global Investments’s Revance Therapeutics, Inc. RVNC Stock Holding History

Mirae Asset Global Investments’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,496
Closed -$10.7K – 1685
2024
Q4 		$10.7K Sell
3,496
-295
-8% -$1.28K ﹤0.01% 1509
2024
Q3 		$20.3K Buy
3,791
+673
+22% +$3.35K ﹤0.01% 1432
2024
Q2 		$8.04K Sell
3,118
-34,500
-92% -$118K ﹤0.01% 1475
2024
Q1 		$1.11M Sell
37,618
-405
-1% -$2.4K ﹤0.01% 1477
2023
Q4 		$334K Buy
38,023
+126
+0.3% +$1.03K ﹤0.01% 2155
2023
Q3 		$435K Buy
37,897
+166
+0.4% +$3.19K ﹤0.01% 1952
2023
Q2 		$955K Buy
37,731
+689
+2% +$21.5K ﹤0.01% 1593
2023
Q1 		$1.19M Sell
37,042
-40
-0.1% -$1.25K ﹤0.01% 1448
2022
Q4 		$685K Buy
37,082
+5,493
+17% +$126K ﹤0.01% 1712
2022
Q3 		$853K Buy
31,589
+9,964
+46% +$202K ﹤0.01% 1574
2022
Q2 		$299K Buy
+21,625
New +$333K ﹤0.01% 1990
2017
Q1 		– Sell
-15,633
Closed -$323K – 672
2016
Q4 		$323K Buy
+15,633
New +$262K 0.01% 447

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mirae Asset Global Investments's RVNC Position: Q1 2025 in Review

Mirae Asset Global Investments sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 3,496 shares — an estimated $10.7K sold.

Mirae Asset Global Investments first reported a position in RVNC in Q4 2016 and held it in 12 quarters. The position peaked at $1.19M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Mirae Asset Global Investments reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 3,496 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $10.7K.
  • Mirae Asset Global Investments first reported a position in Revance Therapeutics, Inc. in Q4 2016 and held it in 12 quarters.
  • Mirae Asset Global Investments's Revance Therapeutics, Inc. position peaked at $1.19M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Mirae Asset Global Investments's 13F filing for Q1 2025, filed 24 Apr 2025.